A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Jan 2019
At a glance
- Drugs Clazosentan (Primary)
- Indications Cerebral vasospasm
- Focus Registrational; Therapeutic Use
- Acronyms REACT
- Sponsors Idorsia Pharmaceuticals
- 21 Dec 2018 Planned primary completion date changed from 19 Jan 2021 to 1 Nov 2020.
- 18 Dec 2018 Planned initiation date changed from 1 Dec 2018 to 10 Jan 2019.
- 19 Nov 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2018.